Chang AE. Karnell LH. Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83: 1664–1678. https://doi.org/10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g.

Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989–98. https://doi.org/10.1001/archophthalmol.2009.208.

Article  PubMed  Google Scholar 

Silva-Rodriguez P. Fernandez-Diaz D. Bande M. Pardo M. Loidi L. Blanco-Teijeiro MJ. GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma. Cancers (Basel) 2022;14 https://doi.org/10.3390/cancers14133066.

Kolandjian NA, Wei C, Patel SP, Richard JL, Dett T, Papadopoulos NE, Bedikian AY. Delayed systemic recurrence of uveal melanoma. Am J Clin Oncol. 2013;36:443–9. https://doi.org/10.1097/COC.0b013e3182546a6b.

Article  PubMed  PubMed Central  Google Scholar 

Beasley AB, Chen FK, Isaacs TW, Gray ES. Future perspectives of uveal melanoma blood based biomarkers. Br J Cancer. 2022;126:1511–28. https://doi.org/10.1038/s41416-022-01723-8.

Article  PubMed  PubMed Central  Google Scholar 

Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30:1370–80. https://doi.org/10.1093/annonc/mdz176.

Article  CAS  PubMed  Google Scholar 

Collaborative Ocular Melanoma Study, G. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001;119:670–676, https://doi.org/10.1001/archopht.119.5.670.

Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, et al. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist. 2020;25:e147–59. https://doi.org/10.1634/theoncologist.2019-0244.

Article  PubMed  Google Scholar 

Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18:168–82. https://doi.org/10.1038/nri.2017.131.

Article  CAS  PubMed  Google Scholar 

McGrail DJ, Pilie PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32:661–72. https://doi.org/10.1016/j.annonc.2021.02.006.

Article  CAS  PubMed  Google Scholar 

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. https://doi.org/10.1186/s13073-017-0424-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfeifer GP. Mechanisms of UV-induced mutations and skin cancer. Genome Instab Dis. 2020;1:99–113. https://doi.org/10.1007/s42764-020-00009-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dousset L. Poizeau F. Robert C. Mansard S. Mortier L. Caumont C. Routier É. Dupuy A. Rouanet J. Battistella M. et al. Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy. JCO Prec Onco 2021;1821–1829, https://doi.org/10.1200/po.21.00084.

Hilke FJ. Sinnberg T. Gschwind A. Niessner H. Demidov G. Amaral T. Ossowski S. Bonzheim, I. Rocken M. Riess O et al. Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. Cancers (Basel) 2020;12 https://doi.org/10.3390/cancers12092359.

Mobuchon L. Battistella A. Bardel C. Scelo G. Renoud A. Houy A. Cassoux N. Milder M. Cancel-Tassin G. Cussenot O. et al. A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus.

Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856–9. https://doi.org/10.1136/jmedgenet-2011-100156.

Article  CAS  PubMed  Google Scholar 

Rai K, Pilarski R, Boru G, Rehman M, Saqr AH, Massengill JB, Singh A, Marino MJ, Davidorf FH, Cebulla CM, et al. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2017;56:168–74. https://doi.org/10.1002/gcc.22424.

Article  CAS  PubMed  Google Scholar 

Li Y, Shi J, Yang J, Ge S, Zhang J, Jia R, Fan X. Uveal melanoma: progress in molecular biology and therapeutics. Ther Adv Med Oncol. 2020;12:1758835920965852. https://doi.org/10.1177/1758835920965852.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobrinski DA, Yang H, Kittaneh M. BAP1: role in carcinogenesis and clinical implications. Transl Lung Cancer Res. 2020;9:S60–6. https://doi.org/10.21037/tlcr.2019.11.24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM, Vaarwater J, Kockx CE, Paridaens D, Naus NC, Nellist M, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27:1321–30. https://doi.org/10.1038/modpathol.2014.43.

Article  CAS  PubMed  Google Scholar 

Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, van de Nes J, Klein-Hitpass L, Hinnebusch AG, Horsthemke B, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45:933–6. https://doi.org/10.1038/ng.2674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3:1122–9. https://doi.org/10.1158/2159-8290.CD-13-0330.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yavuzyigitoglu, S.; Koopmans, A.E.; Verdijk, R.M.; Vaarwater, J.; Eussen, B.; van Bodegom, A.; Paridaens, D.; Kilic, E.; de Klein, A.; Rotterdam Ocular Melanoma Study, G. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. Ophthalmology 2016, 123, 1118–1128, https://doi.org/10.1016/j.ophtha.2016.01.023.

Mobuchon L, Derrien AC, Houy A, Verrier T, Pierron G, Cassoux N, Milder M, Deleuze JF, Boland A, Scelo G, et al. Different Pigmentation Risk Loci for High-Risk Monosomy 3 and Low-Risk Disomy 3 Uveal Melanomas. J Natl Cancer Inst. 2022;114:302–9. https://doi.org/10.1093/jnci/djab167.

Article  CAS  PubMed  Google Scholar 

Ewens KG, Kanetsky PA, Richards-Yutz J, Al-Dahmash S, De Luca MC, Bianciotto CG, Shields CL, Ganguly A. Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Invest Ophthalmol Vis Sci. 2013;54:5721–9. https://doi.org/10.1167/iovs.13-12195.

Article  CAS  PubMed  Google Scholar 

Bornfeld N, Prescher G, Becher R, Hirche H, Jöckel KH, Horsthemke B. Prognostic implications of monosomy 3 in uveal melanoma. The Lancet. 1996;347:1222–5. https://doi.org/10.1016/S0140-6736(96)90736-9.

Article  Google Scholar 

Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63:93–102. https://doi.org/10.4103/0301-4738.154367.

Article  PubMed  PubMed Central  Google Scholar 

Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31:241–57. https://doi.org/10.1038/eye.2016.275.

Article  CAS  PubMed  Google Scholar 

Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205–9. https://doi.org/10.1158/0008-5472.CAN-04-1750.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596–603. https://doi.org/10.1016/j.ophtha.2012.02.017.

Article  PubMed  Google Scholar 

McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48–58. https://doi.org/10.1001/archopht.1977.04450010050004.

Article  CAS  PubMed  Google Scholar 

de Bruyn DP, van Poppelen NM, Brands T, van den Boom SC, Eikenboom E, Wagner A, van Veghel-Plandsoen MM, Geeven G, Beverloo B, van Rij CM, et al. Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma. Invest Ophthalmol Vis Sci. 2024;65:11. https://doi.org/10.1167/iovs.65.2.11.